Effects of Black Tea Intake on Serum Lipids
- Conditions
- Hypercholesterolemia
- Interventions
- Dietary Supplement: Tea Treatment GroupDietary Supplement: Placebo
- Registration Number
- NCT01882283
- Lead Sponsor
- University of Minnesota
- Brief Summary
A diet-controlled clinical trial which attempts to provide estimates of the effect of black tea consumption on serum lipids under tightly controlled conditions, including a controlled diet. Mildly hypercholesterolemic individuals (total cholesterol levels between 4.9 and 6.7 mmol/L, 190 and 260 mg/dl), non-smoking, chronic disease-free individuals were enrolled in a 15-week, double blind, randomized crossover trial, during which they consumed a controlled low-flavonoid diet plus 5 cups of black tea or a tea-like placebo over two 4-week treatment periods.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 57
- between 45-65 years old
- mildly hypercholesterolemic (total cholesterol levels between 4.9 and 6.7 mmol/L, 190 and 260 mg/dl)
- high-density lipoprotein cholesterol (HDL-C) between 0.9 and 1.6 mmol/L (35 and 65 mg/dl)
- triglyceride (TG) concentrations below 6.8 mmol/L (600 mg/dl)
- habitually consumed a typical American diet with low dietary flavonoid intake (<4 one-half cup servings of fruits and vegetables/day) and low intake (<1 serving/day) of soy-rich foods, nuts, herbs, and spices (besides salt and pepper)
- aspartate aminotransferase (AST) between 0 and 55 mg/L
- creatinine between 70.7 and 150.3 mmol/L (0.8 and 1.7 mg/dl)
- glucose between 3.3 and 6.4 mmol/L (60 and 115 mg/dl)
- current smoker
- usage of high amounts of antioxidant vitamin supplements (>3 times the Recommended Dietary Allowance (RDA) of vitamins E, C, and selenium, or >10 mg/day of beta carotene)
- had been diagnosed with diabetes, coagulation disorders, chronic pulmonary disease, current active malignancy, renal disease requiring dialysis, malabsorption, or gastrointestinal disorders, or had a history of cardiovascular disease.
- antihypertensive, immunosuppressive, cholesterol lowering, or anticoagulant medications
- consuming >3 servings of alcohol daily
- Pre-menopausal (women)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Tea Treatment Group Tea Treatment Group 5 cups brewed tea beverage per day for 28 days, brewed from 700 mg of black tea solids per cup Placebo Group Placebo 5 cups tea-like placebo per day for 28 days. Placebo was exactly matched to tea except for flavonoid composition. Placebo was flavonoid-free.
- Primary Outcome Measures
Name Time Method Serum lipid levels 4 weeks Serum lipid levels (total cholesterol, LDL-C, HDL-C, triglycerides, LDL-C+HDL-C fraction, LDL-C/HDL-C ratio) were assessed at the end of a 28-day treatment period
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
General Clinical Research Center, University of Minnesota
🇺🇸Minneapolis, Minnesota, United States